Insights
Clinician in the AI Loop: a faulty solution to a thorny problem
The vast majority of AI medical devices rely on having a clinician verify their outputs. On the surface this seems good for safety, but in reality it’s a short-sighted solution to a much deeper problem.
Is post-market surveillance of AI devices working?
Pre-market review only interrogates AI device performance at a single point in time, often in laboratory conditions. This is a common yet completely valid criticism of the regulatory process. Therefore consensus amongst regulators and academics is that the real-world safety of AI devices must be monitored post-market in real time.
But is anyone actually doing it?
Health economic insights from Hardian Summit 2026
Software and AI medical devices (AI/SaMD) are solving clinical problems at speed. Healthcare systems, though, won't adopt a technology that works brilliantly if they can't make an economic case for it. At the Hardian Summit 2026, we hosted a workshop on Health Economics and Outcomes Research for professionals new to the field.
Validating software and AI tools in your QMS
Computer software validation has never mattered more in the age of AI. Software now sits at the centre of most medical device quality systems. A medical device manufacturer may use software to track requirements, control documents, record complaints, manage CAPAs, train staff and maintain technical documentation.
From AI regulation to NHS adoption: Insights from Hardian Health Tech Summit 2026
From AI regulation to NHS adoption, here are the biggest insights from Hardian Health Tech Summit 2026 and what they mean for HealthTech companies.
Do I need to notify the MHRA about my clinical investigation?
Do you need MHRA Notice of No Objection for your SaMD study? Learn when NoNo is required, how to apply, and what documentation regulators expect.
7 Practical Ways a Literature Review De-Risks an SaMD Pivotal Clinical Study
A strong literature review shapes SaMD study design, from comparators to sample size. Learn how it reduces risk in pivotal clinical studies.
NICE’s evolving HealthTech approach: what it means for the NHS and industry
The NHS has long been a testing ground for innovation, but scaling new technologies has often been slower and fragmented. Now, NICE is changing HealthTech adoption in the NHS through a more structured and flexible approach.
What is the best way of assessing the economic value of AI in radiology?
We recently published a Systematic Literature Review (SLR) in European Radiology, developed in collaboration with Prof. Zanca at the European Commission, so we wanted to share our progress on developing best practice guidance for assessing the value of radiology AI.
Are fertility tracking apps regulated?
Fertility tracking apps are widely used, but are they regulated as medical devices? The answer depends on functionality. Some apps that support conception or contraception fall under UK and EU medical device regulations, while others remain outside formal oversight. Understanding when fertility apps are regulated is essential for both users and developers navigating safety, data protection, and compliance.
Risk Frameworks Beyond ISO 14971 – Why AI Medical Devices Break Traditional Risk Files
ISO 14971 has been central to medical device risk management for over two decades. It provides a structured and defensible methodology: identify hazards, analyse hazardous situations, estimate and evaluate risk, implement controls, and determine whether residual risk is acceptable in light of clinical benefit.
Science Washing in Digital Health: How to Communicate Evidence Responsibly
Science washing in digital health can damage trust and trigger regulatory scrutiny. Learn how to communicate evidence responsibly and build credibility.
Blood pressure, wearables, and FDA General Wellness Guidance: did the rules really change?
In July 2025, the FDA issued a warning letter to WHOOP, stating that measuring blood pressure is a medical device function. But in January 2026, they updated their guidance. What changed? Do the new guidelines really allow wearables to measure blood pressure without regulation or evidence?
The FDA’s 2026 Clinical Decision Support (CDS) Guidance Update - What’s Changed?
It’s been 4 years since the FDA updated their CDS guidance. The new 2026 version brings clarification, more examples, and some pragmatic relaxation of how to interpret the CDS criteria. But are the changes really that substantial?
Creating a global regulatory intelligence database
Many countries around the world currently have no central database of their medical devices, or have ones that are not quite fit for purpose. We are building HaRi - a global regulatory intelligence database - bringing medical device regulatory data into modern era of innovation. Our hope is that by raising the veil of transparency across all medical devices, the entire industry can benefit.
Can you use Gen AI to create your regulatory documentation?
We're witnessing a rapid rise of the use of generative AI in the medical device regulatory space to produce and review documentation. This raises the question - If all compliance documentation is created by a machine, and all compliance documentation is audited by a machine - has any compliance actually happened?
Key takeaways from ISPOR Europe Health Economics trends for SaMD
Hardian team members Lucy Gregory (Health Economics Consultant) and Dr Felicity Lock (Senior Clinical Associate) recently returned from ISPOR Europe, an international conference in Glasgow dedicated to Health Economics and Outcomes Research. If ISPOR is unfamiliar territory, this overview explains why it should matter to anyone developing AI and software as a medical device.
MyCardium’s quadruple regulatory cleared cardiac AI platform
MyCardium AI is a rapidly growing UK-based company delivering advanced core-lab services, now with two CE-marked and FDA-cleared AI medical devices - 1CMR Pro and EchoConfidence - built on decades of leading academic research. With Hardian Health as a strategic partner, MyCardium navigated complex regulatory pathways with exceptional speed and success. How did they do it?